Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

RAB0607

Sigma-Aldrich

Human APOA1 / Apolipoprotein A-I ELISA Kit

Sign Into View Organizational & Contract Pricing

UNSPSC Code:
41116158
NACRES:
NA.32

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable

input

sample type plasma
sample type serum
sample type cell culture supernatant(s)

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 0.08 ng/mL
standard curve range: 0.082-20 ng/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... APOA1(335)

General description

Apolipoprotein A-1 (APOA1) is a major constituent of high-density lipoprotein (HDL) cholesterol. It aids in reverse cholesterol transport (RCT). In addition, apoA1 is also implicated in the pathways that protect endothelial functions, induce nitric oxide-mediated vasodilatation, and reduce vascular cell adhesion molecule-1 (VCAM-I) expression. APOA1 stimulates proliferation by inhibiting apoptosis. The ApoA enzyme-linked immunosorbent assay (ELISA) kit provides for the quantitative measurement of ApoA1 in cell culture supernatants, plasma, and serum.
The ApoA ELISA kit provides for the Quantitative measurement of ApoA1 in Cell Culture Supernatants, Plasma and Serum.

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Kit Components Also Available Separately

Product No.
Description
SDS

  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS

  • RABSTOP3ELISA Stop Solution (Item I)SDS

  • RABWASH420X Wash Buffer (Item B)SDS

Pictograms

Corrosion

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Met. Corr. 1

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mathilde Mouchiroud et al.
JCI insight, 4(15) (2019-08-09)
Nonalcoholic fatty liver disease (NAFLD) prevails in obesity and is linked to several health complications including dyslipidemia and atherosclerosis. How exactly NAFLD induces atherogenic dyslipidemia to promote cardiovascular diseases is still elusive. Here, we identify Tsukushi (TSK) as a hepatokine
Jolanta Parada-Turska et al.
Antioxidants (Basel, Switzerland), 9(9) (2020-09-25)
Paraoxonase 1 (PON1) is the high density lipoprotein-associated esterase which inhibits the development of atherosclerosis by metabolizing lipid peroxidation products as well as hydrolyzing proatherogenic metabolite of homocysteine (Hcy), Hcy thiolactone, which otherwise reacts with lysine groups of proteins, thus
Thomas Lundåsen et al.
PloS one, 15(3), e0229322-e0229322 (2020-03-17)
Tetradecylthioacetic acid (TTA) is a synthetic fatty acid with a sulfur substitution in the β-position. This modification renders TTA unable to undergo complete β-oxidation and increases its biological activity, including activation of peroxisome proliferator activated receptors (PPARs) with preference for
Manja Koch et al.
Journal of lipid research, 58(6), 1196-1203 (2017-04-04)
The presence of apoC-III on HDL impairs HDL's inverse association with coronary heart disease (CHD). Little is known about modifiable factors explaining variation in HDL subspecies defined according to apoC-III. The aim was to investigate cross-sectional associations of anthropometry and
Michael A Tortorici et al.
Clinical pharmacology in drug development, 8(5), 628-636 (2018-09-22)
CSL112 (Apolipoprotein A-I [human]) is an intravenous preparation of apolipoprotein A-I (apoA-I), formulated with phosphatidylcholine (PC) and stabilized with sucrose, in development to prevent early recurrent cardiovascular events following acute myocardial infarction (AMI). This phase 1 study was designed to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service